• PBR Staff Writer
• 07 Nov, 2019

Regeneron Pharmaceuticals has entered into a research collaboration and option licencing agreement with Vyriad to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer. Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments
Read more...